human immunoglobulin (pH4) for intravenous injection / Peking Union Medical College - LARVOL DELTA

Symbiotic-Lung-14: A Phase 2 Trial of PD-1/VEGF Bispecific Antibody, PF-08634404, Plus Chemotherapy in 1L Transformed SCLC (IASLC-WCLC 2026) - P2 | "PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets programmed death 1 (PD-1) and vascular endothelial growth factor (VEGF)...Approximately 40 patients will be enrolled to receive PF-08634404 in combination with etoposide and carboplatin, followed by maintenance therapy with PF-08634404...Exploratory endpoints include quality of life and biomarkers. Enrollment has begun."

Bispecific • IO biomarker • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • EGFR • PD-1

EBV-associated autoimmune glial fibrillary acidic protein astrocytopathy with lumbosacral leptomeningeal enhancement: a case report and literature review. (PubMed, Neurol Sci) - "EBV-associated GFAP-A can manifest as isolated lumbosacral leptomeningeal enhancement in the absence of classic intracranial radial perivascular enhancement. Combined antiviral and immunotherapy demonstrates favorable short-term efficacy, whereas long-term, B-cell-targeted maintenance therapy may reduce the risk of relapse."

IO biomarker • Journal • Review • Back Pain • Epstein-Barr Virus Infections • Immunology • Infectious Disease • Lumbar Back Pain • Movement Disorders • Musculoskeletal Pain • Pain • GFAP

The Autophagy-Inflammasome Axis as a Molecular Switch: From Persistent Inflammation to Vascular Remodeling in IVIG-Resistant Kawasaki Disease. (PubMed, Int J Mol Sci) - "Intravenous immunoglobulin (IVIG) resistance occurs in 10-20% of children with Kawasaki disease (KD) and is associated with a 3- to 5-fold higher risk of coronary artery lesions (CALs). This review provides a systematic framework for understanding how IVIG resistance transitions to irreversible CALs. It also identifies candidate biomarkers (e.g., S100A12, mtDNA, and MCM8) and therapeutic targets (autophagy inducers, NLRP3 inhibitors, USP7 inhibitors, and anakinra) that could enable earlier intervention."

Journal • Review • Inflammation • Vasculitis • IL1B • MCM8 • NLRP3 • S100A12 • STING • TGFB1 • TGFB2 • USP7

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight. (PubMed, Hematol Oncol) - P=N/A | "Idiopathic multicentric Castleman disease (iMCD) is rare and life-threatening; although siltuximab is standard first-line therapy, a substantial proportion of patients are refractory or experience relapse...After fludarabine/cyclophosphamide lymphodepletion, she received 1 × 106 CAR + T cells/kg of autologous CD19 CAR T cells on day 0...Panhypogammaglobulinemia was managed with intravenous immunoglobulin replacement. At > 12 months post-infusion, she remains in complete, treatment-free remission. This observation supports a B-cell-centric model for refractory iMCD-IPL and motivates prospective evaluation of CD19 CAR T-cell therapy."

Journal • Hematological Disorders • Inflammation • Rare Diseases

A Case Report of Acute Intermittent Porphyria Accompanied by Severe Peripheral Neuropathy. (PubMed, Diagnostics (Basel)) - "She was initially misdiagnosed with Guillain-Barré syndrome (GBS) and received intravenous immunoglobulin and systemic glucocorticoids...The triad of absent albuminocytologic dissociation in cerebrospinal fluid, preceding visceral symptoms, and inadequate response to standard first-line GBS therapy should immediately raise clinical suspicion for AIP. Enhanced clinical awareness of this rare disorder and timely implementation of urinary PBG screening are of paramount importance to prevent irreversible neurological complications and optimize long-term patient outcomes."

Journal • Cardiovascular • Genetic Disorders • Heart Failure • Hematological Disorders • Hepatology • Liver Failure • Metabolic Disorders • Pain • Peripheral Neuropathic Pain • Rare Diseases • HMBS

Intravenous Immunoglobulin Reveals a Novel Protective Mechanism: Targeting the GBP5-Driven Pyroptosis Axis in Experimental Colitis. (PubMed, Pharmaceuticals (Basel)) - "IVIG suppressed GBP5/NLRP3/CASP1 activation, reduced GSDMD cleavage, and significantly decreased IL-1β production (while showing a decreasing trend for IL-18). IVIG ameliorates colitis by inhibiting the GBP5/NLRP3/CASP1-mediated pyroptosis pathway, highlighting its potential as a targeted therapy for ulcerative colitis."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • GBP5 • IL18 • IL1B • NLRP3

Toxic epidermal necrolysis induced by exposure to S,S-dimethyl cyanoimidodithiocarbonate: case report and nursing experience. (PubMed, Front Med (Lausanne)) - "Key treatment regimens include systemic glucocorticoids, cyclosporine, intravenous immunoglobulin, and single-dose infliximab, combined with nursing care for impaired skin and mucosal integrity, multidisciplinary pain management, and supportive therapy. The patient had approximately 60% body surface area (BSA) involvement upon admission. After 20 days of intensive treatment and personalized nursing, the patient's skin lesions had nearly healed, and the condition improved sufficiently to allow discharge."

Journal • Pain • Steven-Johnson Syndrome

Clinical, Genetic, and Functional Characterization of Novel NFKB1 Variants in Chinese Patients with Primary Immunodeficiency. (PubMed, Clin Exp Immunol) - "This study represents the first and largest case series of Chinese patients with NF-κB1-related diseases, providing molecular characterization for three novel variants. In this limited case series, the observed delayed onset and frequent hepatic complications in our cohort may reflect regional factors, such as HBV endemicity, or ascertainment bias. Our findings underscore that suspected AOSD accompanied by hypogammaglobulinemia warrants immediate genetic investigation. Early diagnosis is essential to prioritize immunoglobulin replacement and prevent fatal complications from immunosuppressive therapy."

Journal • Bronchiectasis • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Oncology • Pneumonia • Primary Immunodeficiency • Pulmonary Disease • Respiratory Diseases • Septic Shock

Efficacy and Safety of Ianalumab in Chinese Patients with Sjögren’s Disease: Subgroup Analysis from Two Global Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies (NEPTUNUS-1 and NEPTUNUS-2) (EULAR 2026) - P3 | "Ianalumab is a fully human immunoglobulin G1 monoclonal antibody (IgG1 mAb) with a novel dual mechanism of action that depletes B cells through enhanced antibody- dependent cellular cytotoxicity (ADCC) and also inhibits their activation and survival via BAFF-R blockade...Stable doses of background immunosuppressants, including MTX (≤25 mg/Wk), HCQ (≤400 mg/day), AZA (≤150 mg/day), and prednisone (≤10 mg/day) were allowed alone or in combination in both studies...Conclusions In the Chinese population, ianalumab 300 mg QM demonstrated consistent numerical improvements over placebo in both the primary and most secondary endpoints, indicating improvements in global disease activity and also symptom burden reduction. In addition, ianalumab was safe and overall well tolerated in Chinese patients, confirming its benefit-risk profile align with those observed in the overall population."

Clinical • P3 data • Immunology • Sjogren's Syndrome

Intravenous immunoglobulin enhances intestinal stem cell regeneration to mitigate radiation-induced enteritis via promoting β-catenin nuclear translocation. (PubMed, Stem Cell Reports) - "Mechanistically, IVIg promoted β-catenin nuclear translocation, and the β-catenin inhibitor MSAB diminished IVIg's radioprotective effects. Collectively, IVIg combats RIE by enhancing ISC regeneration via β-catenin nuclear translocation, highlighting its potential as an RIE therapeutic candidate."

Journal • Gastrointestinal Disorder • Oncology • Peritoneal Cancer • OLFM4

Catastrophic antiphospholipid syndrome complicated with multiple infections: a case report. (PubMed, Front Immunol) - "A diagnosis of autoimmune hemolytic anemia and thrombocytopenia was established, and high-dose methylprednisolone combined with intravenous immunoglobulin therapy was initiated. On day 4, a tricuspid valve thrombus was detected and argatroban was initiated...Early manifestations of CAPS may be atypical, so early identification is crucial for treatment. Following steroid pulse therapy, vigilance for fungal infections is essential, with empirical antifungal therapy initiated when necessary."

Journal • Autoimmune Hemolytic Anemia • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Leukopenia • Subarachnoid Hemorrhage • Thrombocytopenia • Thrombosis

Kikuchi-Fujimoto disease complicated with brachial plexus neuritis in a young woman: a case report and review of the literature. (PubMed, J Med Case Rep) - "We report a rare case of KFD-associated brachial plexus neuritis emerging shortly after lymph node biopsy. We hypothesize that surgical positioning or traction, superimposed on the KFD inflammatory background, may precipitate this condition. Clinicians should be vigilant for this complication to ensure prompt anti-inflammatory treatment and avoid unnecessary secondary surgeries."

Journal • Inflammation • Pain

Combined mesenchymal stem cells and telitacicept therapy for Evans syndrome refractory to various immunosuppressive: a case report. (PubMed, Res Pract Thromb Haemost) - "A 41-year-old woman with refractory ES, unresponsive to multiple therapies including corticosteroids, intravenous immunoglobulin, rituximab, thrombopoietin receptor agonists, daratumumab, and splenectomy, was treated with combined telitacicept (160 mg weekly) and MSCs (2 × 106 cells/kg weekly). This case suggests that combined therapy with telitacicept and MSCs may represent an effective therapeutic option for patients with refractory ES. The complementary immunosuppressive mechanisms of BAFF/APRIL blockade and MSC-mediated immune regulation may provide synergistic disease control and warrant further investigation in larger clinical studies."

Journal • Autoimmune Hemolytic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Limbic encephalitis associated with anti-Hu antibody induced by atezolizumab treatment for small cell lung cancer: A case report. (PubMed, Oncol Lett) - "After treatment with high-dose steroids and intravenous immunoglobulin, the neurological symptoms of the patient (including confusion, short-term memory loss, disorientation, and impaired calculation ability) remained stable for 3 months, after which the patient was lost to follow-up. ICIs may accelerate autoimmune reactions that target paraneoplastic origin autoantigens. Clinicians should be alert to the risk of ICI-induced paraneoplastic neurological syndromes in patients with tumors, such as small cell lung cancer, that are traditionally associated with paraneoplastic neurological syndromes."

Journal • CNS Disorders • Cognitive Disorders • Immunology • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

The effects of intravenous immunoglobulin on intestinal inflammation: a systematic review of animal and clinical studies. (PubMed, PeerJ) - "Further work is needed to improve the rigour and transparency of preclinical studies and to conduct small, well-designed prospective clinical studies in clearly defined niche indications to clarify any potential role of IVIg within the expanding therapeutic armamentarium for intestinal inflammation. PROSPERO ID (CRD420251051592)."

Journal • Review • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis

Can IVIG Intervene in AD? Insights from Animal Experiments and Clinical Trials-A Systematic Review and Synthesis Without Meta-Analysis. (PubMed, Int J Mol Sci) - "The clinical safety of intravenous immunoglobulin (IVIG) is well-established, offering potential as a "one-drug, multi-target" intervention for Alzheimer's disease (AD)...IVIG possesses a favorable safety profile and can ameliorate AD symptoms, yet efficacy varies considerably between trials. To advance treatment, future research should investigate the reasons for these variances and establish a standardized system for evaluating preclinical IVIG interventions, thereby facilitating the development of specific IVIG products for AD."

Clinical • Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

PERSISTENT HYPONATREMIA AS A DISTINCTIVE FEATURE OF HHV-6B ENCEPHALITIS IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A CASE SERIES (EBMT 2026) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia during engraftment after HSCT or CRS post-CAR-T therapy could indicate HHV-6B encephalitis in children, highlighting the need for CNS evaluation for diagnosis."

Clinical • IO biomarker • Bone Marrow Transplantation • Cardiovascular • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Inflammation • Juvenile Myelomonocytic Leukemia • Movement Disorders • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • Transplantation • CD7

Fetal echocardiographic surveillance in anti-SSA/Ro-SSB/La-Positive systemic lupus erythematosus pregnancies: risk stratification of congenital heart block. (PubMed, Rheumatology (Oxford)) - "SLE pregnancies with anti-SSA/Ro-SSB/La antibodies and suboptimal gestational conditions constitute a distinct high-risk subgroup. A management strategy through risk-stratified serial fetal AVI monitoring allows for precise treatment identification, significantly improving neonatal outcomes while avoiding unnecessary interventions."

Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Fulminant disseminated human parvovirus B19 infection: Case report. (PubMed, IDCases) - "Despite negative B19-specific IgM, the patient improved after four weeks of supportive care and two courses of intravenous immunoglobulin, with recovery of renal, hepatic, and respiratory function and resolution of rectal lesions. Disseminated HPV B19 infection should be considered in unexplained multiorgan dysfunction, even in the absence of rash or IgM seroconversion. Early PCR-based testing of blood and affected tissues can be diagnostic."

Journal • Colorectal Cancer • Critical care • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Nephrology • Thrombocytopenia

Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease. (PubMed, Front Immunol) - "The expression levels of S100A8/A9, S100A12, TNF, TNFSF8/10, and interferon-α were consistent with the transcriptomic data. Our findings reveal the immune landscape in IVIG non-responsive KD and suggest potential targets for alternative therapies."

Journal • Inflammation • MYD88 • S100A12 • S100A8 • TLR4 • TNFSF8

Persistent hyponatremia as a distinctive feature of HHV-6B encephalitis in pediatric hematopoietic stem cell transplant recipients: A case series (ASH 2025) - "All five patients were administered antiviral therapy comprising ganciclovir, foscarnet, and intravenous immunoglobulin. Persistent hyponatremia may act as a distinctive clinical indicator of HHV-6B encephalitis in pediatric patients undergoing HSCT. The underlying mechanisms require further investigation."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Chronic Myelomonocytic Leukemia • CNS Disorders • Dermatology • Endocrine Disorders • Epilepsy • Heart Failure • Hematological Malignancies • Infectious Disease • Juvenile Myelomonocytic Leukemia • Leukemia • Movement Disorders • Myelodysplastic Syndrome • Nephrology • Pediatrics • Pruritus • Rare Diseases • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • CD7

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia (ASH 2025) - P2, P3 | "Use of additional, stable Background ITPtherapy is permitted, including corticosteroids, thrombopoietin receptor agonists, and fostamatinib, as isuse of rescue therapy (corticosteroids, intravenous immunoglobulin, platelet transfusion) whenindicated. Given promising, early-stage results for anti-CD38 treatment in patients who have beendifficult to manage on current therapies, this global study will evaluate the efficacy and safety ofsubcutaneous mezagitamab as a potential novel therapy for patients with ITP who have had aninsufficient response or intolerance to prior therapy."

Clinical • P3 data • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Real-world safety and effectiveness of hetrombopag in patients with primary immune thrombocytopenia (ASH 2025) - P | "Management of ITP remains challenging, particularly forpatients who are refractory or intolerant to first-line treatments such as corticosteroids or intravenousimmunoglobulin (IVIg). Hetrombopag demonstrated favorable real-world safety and effectiveness in patients withITP, leading to sustained improvements in platelet counts and reduced reliance on concomitanttherapies. These findings provide meaningful evidence supporting the use of hetrombopag in routineclinical practice and underscore its potential as a core component in the long-term management of ITP."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

A Phase III Clinical Trial Program Investigating the Efficacy and Safety of Ianalumab in Patients with Primary Immune Thrombocytopenia (VAYHIT1 and VAYHIT2) and Warm Autoimmune Hemolytic Anemia (VAYHIA) (ASH 2023) - P2, P3 | "Ianalumab is a novel, fully human immunoglobulin G1 monoclonal antibody that targets BAFF receptor (BAFF-R) and has a unique dual mechanism of action: direct antibody-dependent cellular cytotoxicity-mediated B-cell depletion and inhibition of B-cell differentiation, proliferation and survival via blockade of BAFF-R-mediated signaling...Thrombopoietin receptor agonists (TPO-RAs), such as eltrombopag, are commonly used second-line ITP treatments and often achieve a response; however, responses are rarely maintained once treatment ends, so chronic administration is typically required. For wAIHA, few treatments have been approved, and patients rarely achieve durable responses on CS or off-label rituximab... These trials have been designed based on the hypothesis that, when administered early in disease progression, medical therapy targeting complementary physiological pathways may restore self-tolerance in patients with ITP and wAIHA. Ianalumab in combination with..."

Clinical • P3 data • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Epidemiologic trends of Kawasaki Disease and the potential impact of COVID-19 pandemic in Shanghai from 2018 through 2022. (PubMed, Chin Med J (Engl)) - "The incidence of KD in Shanghai showed a downward trend during 2018-2022 compared to 2013-2017. The containment measures implemented during the COVID-19 pandemic, such as citywide suspension of work and school closures, may have affected the incidence of KD."

Journal • Cardiovascular • Infectious Disease • Novel Coronavirus Disease • Pediatrics